Core Insights - Becton, Dickinson and Company (BDX) is expanding its partnership with Ypsomed to develop a 5.5 mL version of the BD Neopak XtraFlow Glass Prefillable Syringe, aimed at meeting the growing demand for large-volume subcutaneous self-injection [2][3][4] Company Developments - The new 5.5 mL syringe is designed for full compatibility with Ypsomed's YpsoMate 5.5 autoinjector, enhancing the ease of use for patients requiring high-dose biologic medicines [3][4] - The syringe features advanced technology, including a shorter 8-millimeter needle and thinner cannula walls, to improve flow and reduce injection time, addressing common issues with large-volume biologics [9][8] - The partnership aims to strengthen BD's competitive positioning in drug delivery systems, particularly as biologics pipelines shift toward higher-dose, subcutaneous formulations [6][4] Market Trends - The prefilled syringes market is projected to reach $24.13 billion by 2026, with a CAGR of 11.6% through 2035, driven by the rising demand for safe and convenient drug delivery systems and the increasing use of biologics and injectable therapies [13] Financial Performance - Following the announcement of the partnership, BDX shares increased by 1.4%, with a 13.7% rise over the past six months, slightly below the industry growth of 13.9% and the S&P 500's 10.4% increase [5]